Relationship between event rates and treatment effects in clinical site differences within multicenter trials: an example from primary Pneumocystis carinii prophylaxis

Απλή σελίδα τεκμηρίου
dc.contributor.authorIoannidis, J. P.en
dc.contributor.authorDixon, D. O.en
dc.contributor.authorMcIntosh, M.en
dc.contributor.authorAlbert, J. M.en
dc.contributor.authorBozzette, S. A.en
dc.contributor.authorSchnittman, S. M.en
dc.date.accessioned2015-11-24T18:54:32Z
dc.date.available2015-11-24T18:54:32Z
dc.identifier.issn0197-2456-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18697
dc.rightsDefault Licence-
dc.subjectAIDS-Related Opportunistic Infections/*prevention & controlen
dc.subjectAnti-Infective Agents/*therapeutic useen
dc.subjectControlled Clinical Trials as Topic/*statistics & numerical dataen
dc.subjectDapsone/therapeutic useen
dc.subjectHumansen
dc.subjectMulticenter Studies as Topic/*statistics & numerical dataen
dc.subjectPentamidine/therapeutic useen
dc.subjectPneumocystis Infections/*prevention & controlen
dc.subjectProbabilityen
dc.subjectProportional Hazards Modelsen
dc.subjectSample Sizeen
dc.subjectTreatment Failureen
dc.subjectTrimethoprim-Sulfamethoxazole Combination/therapeutic useen
dc.titleRelationship between event rates and treatment effects in clinical site differences within multicenter trials: an example from primary Pneumocystis carinii prophylaxisen
heal.abstractThe results of multicenter clinical trials may differ across participating clinical sites. We present a diagnostic approach for evaluating this diversity that emphasizes the relationship between the observed event rates and treatment effects. We use as an example a trial of sequential strategies of Pneumocystis prophylaxis in human immunodeficiency virus infection with 842 patients randomly allocated to start prophylaxis with trimethoprim/sulfamethoxazole, dapsone, or pentamidine. Prophylaxis failure rates varied significantly across the 30 clinical sites (0-30.3%, p = 0.002 by Fisher's exact test) with prominent variability in the pentamidine arm (0-63.6%). Starting with oral regimens was better than starting with pentamidine in sites with high rates of events, whereas the three strategies had more similar efficacy in other sites. Sites enrolling fewer patients had lower event rates and had more patients who withdrew prematurely or were lost to follow-up. In a hierarchical regression model adjusting for random measurement error in the observed event rates, starting with trimethoprim/sulfamethoxazole was predicted to be increasingly better than starting with aerosolized pentamidine as the risk of prophylaxis failure increased (p = 0.01), reducing the risk of failure by 47% when the failure rate of pentamidine was 30%, whereas the two regimens were predicted to be equivalent when the failure rate was 17%. Differences in event rates could reflect a combination of heterogeneity in diagnosis, administration of treatments, and disease risk in patients across sites. The evaluation of clinical site differences with a systematic approach focusing on event rates may give further insight in the interpretation of the results of multicenter trials beyond an average treatment effect.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10357498-
heal.journalNameControl Clin Trialsen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1999-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ